ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1672
0,00%
Bitcoin
68.997,25
0,68%
Brent Oil
81,965
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. BeyondSpring Inc (BYSI)

  7. BeyondSpring Inc (BYSI) Notícias

BYSI

BeyondSpring (BYSI)

BeyondSpring Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BYSI
DataHoraFonteTítuloCódigoCompanhia
16/05/202409:00GlobeNewswire Inc.BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
03/05/202408:00GlobeNewswire Inc.BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
29/04/202418:30GlobeNewswire Inc.BeyondSpring Files 2023 Annual Report on Form 20-FNASDAQ:BYSIBeyondSpring Inc
29/04/202418:30GlobeNewswire Inc.BeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsNASDAQ:BYSIBeyondSpring Inc
25/03/202408:00GlobeNewswire Inc.BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerNASDAQ:BYSIBeyondSpring Inc
26/02/202410:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
26/02/202410:00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsNASDAQ:BYSIBeyondSpring Inc
14/02/202418:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BYSIBeyondSpring Inc
10/01/202417:00GlobeNewswire Inc.BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KNASDAQ:BYSIBeyondSpring Inc
18/12/202318:30GlobeNewswire Inc.BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:BYSIBeyondSpring Inc
07/11/202309:00GlobeNewswire Inc.BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 InhibitorsNASDAQ:BYSIBeyondSpring Inc
31/10/202309:00GlobeNewswire Inc.BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere ModelsNASDAQ:BYSIBeyondSpring Inc
30/10/202309:00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:BYSIBeyondSpring Inc
26/10/202309:30GlobeNewswire Inc.SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumNASDAQ:BYSIBeyondSpring Inc
23/10/202308:45GlobeNewswire Inc.SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of DirectorsNASDAQ:BYSIBeyondSpring Inc
27/09/202311:00GlobeNewswire Inc.BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual MeetingNASDAQ:BYSIBeyondSpring Inc
07/09/202309:00GlobeNewswire Inc.BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare ConferenceNASDAQ:BYSIBeyondSpring Inc
20/06/202309:00GlobeNewswire Inc.SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of DirectorsNASDAQ:BYSIBeyondSpring Inc
07/06/202309:00GlobeNewswire Inc.BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTNASDAQ:BYSIBeyondSpring Inc
18/05/202309:30GlobeNewswire Inc.BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual MeetingNASDAQ:BYSIBeyondSpring Inc
12/05/202317:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BYSIBeyondSpring Inc
18/04/202317:32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:BYSIBeyondSpring Inc
18/04/202317:30GlobeNewswire Inc.BeyondSpring Provides Business Update and Reports Year End 2022 Financial ResultsNASDAQ:BYSIBeyondSpring Inc
18/04/202317:30GlobeNewswire Inc.BeyondSpring Files 2022 Annual Report on Form 20-FNASDAQ:BYSIBeyondSpring Inc
01/03/202310:00GlobeNewswire Inc.BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After ImmunotherapyNASDAQ:BYSIBeyondSpring Inc
09/01/202318:30GlobeNewswire Inc.BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing RulesNASDAQ:BYSIBeyondSpring Inc
13/12/202210:00GlobeNewswire Inc.BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical ConferencesNASDAQ:BYSIBeyondSpring Inc
23/05/202211:15GlobeNewswire Inc.Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of ManufacturingNASDAQ:BYSIBeyondSpring Inc
14/04/202213:00TipRanksBeyondspring (BYSI) Receives a Hold from H.C. WainwrightNASDAQ:BYSIBeyondSpring Inc
14/02/202216:23Edgar (US Regulatory)Schedule 13gNASDAQ:BYSIBeyondSpring Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BYSI

Seu Histórico Recente

BOV
COGN3
COGNA ON
LSE
NXG
Nex Group
NASDAQ
ELECW
TSX
DFN
Dividend 15 Split
TSXV
SYR
TSXV
ELE
Elemental Altus Royalties
ASX
SDAKOB
TSXV
MOU
NASDAQ
PACW
PacWest Bancorp
ASX
CRB
Carbine Resources
TSXV
SDX
Sea Dragon Energy Inc.
TSXV
ANM
ASX
PVE
Po Valley Energy
NASDAQ
SPEX
Spherix
TSXV
IF
TSXV
CFD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados